C4 Therapeutics, Inc. CCCC
3.21 USD 0.00 (+0.00%)
At closeNov 3, 2026, 5:33 PM EST
3.20 -0.01 -0.31%
After hours · Nov 3, 5:33 PM ET
3.17 Day range 3.42
1.69 52-week range 5.17
- YTD
- +68.06%
- 1 year
- +29.44%
Financial health
Altman Z-Score
-1.07 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 3
Valuation
P/E -1.5×
FY 2018 5y median -2.3× FY 2025
P/S 4.4×
FY 2018 5y median 9.3× FY 2025
P/B 0.6×
FY 2018 5y median 1.1× FY 2025
P/FCF -1.6×
FY 2018 5y median -2.6× FY 2025
EV/EBITDA -1.4×
FY 2018 5y median -2.5× FY 2025
EV/Sales 4.0×
FY 2018 5y median 10.8× FY 2025
FCF Yield -62.7%
FY 2018 5y median -38.7% FY 2025
Profitability
Gross Margin 77.8%
FY 2018 5y median 100.0% FY 2025
Operating Margin -290.7%
FY 2018 5y median -336.1% FY 2025
Net Margin -292.1%
FY 2018 5y median -296.0% FY 2025
ROE -40.9%
FY 2018 5y median -44.3% FY 2025
ROIC -31.4%
FY 2018 5y median -32.9% FY 2025
ROA -29.2%
FY 2018 5y median -29.8% FY 2025
Growth (YoY)
Revenue 1.0%
FY 2018 FY 2025
Operating Income 12.6%
FY 2018 FY 2025
EPS (diluted) 16.4%
FY 2018 FY 2025
Free Cash Flow -52.0%
FY 2018 FY 2025
Financial Health
Current Ratio 7.8×
FY 2018 5y median 6.4× FY 2025
Quick Ratio 7.8×
FY 2018 5y median 6.4× FY 2025
Debt / Equity 0.2×
FY 2018 5y median 0.3× FY 2025
Net Debt / EBITDA 0.1×
FY 2018 5y median 0.1× FY 2025
Interest Coverage 0.0×
FY 2018 5y median -38.3× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
